The study, conducted by Thomas Murchie, tackles the question with analytical mathematics rather than new animal or human experiments. Its starting point is the three-element Windkessel model, in which the arterial system is represented by a peripheral resistance, a characteristic impedance of the proximal aorta, and a compliance that stores blood during systole and releases it during diastole. In that framework, Ea depends on total systemic resistance, on arterial compliance through the time constant tau, and critically on the durations of systole and diastole. Clinicians, however, rarely measure Ea that way. Instead they use a convenient surrogate, the ratio of end-systolic pressure to stroke volume, which tracks the Windkessel value closely in living subjects but hides the separate contributions of resistance and compliance beneath a single ratio.

Over the years, several laboratories have proposed a compromise: a linear approximation of the form Ea equals R plus k divided by C, where R is a resistance term, C is compliance, and k is a coefficient that must be fitted to data. Empirical studies produced values of k around 0.314 in work by Segers and colleagues in 2002 and 0.42 in work by Chemla and colleagues in 2003. More provocatively, other analyses concluded that compliance contributes almost nothing at all, effectively setting k near zero and reducing Ea to roughly total resistance divided by cycle length. The physiological determinants of k were never described analytically, leaving the field with a scatter of numbers and no principled way to choose among them.

The new paper resolves the ambiguity with a higher-order approximation. By replacing the exponential term in the Windkessel equation with a polynomial expansion and carrying the algebra one step beyond the truncation that yields the k-equals-zero result, Murchie derives a closed-form expression: Ea is approximately total resistance divided by the cardiac cycle length, plus a compliance term whose coefficient k equals one half multiplied by the square of the ratio of diastolic duration to total cycle duration. In other words, k is not a universal constant at all. It is a timing factor, growing as diastole occupies a larger share of the heartbeat, which happens characteristically when the heart rate is low. At high heart rates, where diastole is squeezed short, the compliance term shrinks toward irrelevance, which is precisely why some studies concluded that compliance barely matters.

To test the approximation, the analysis first compared it against the parent Windkessel equation across a deliberately broad parameter space: 693 evenly distributed combinations of total resistance, compliance, and heart rate, spanning values seen in healthy adults and in patients treated for septic and cardiogenic shock. Heart rates of 60, 80, and 100 beats per minute were used, with ejection times adjusted according to the relationship observed during exercise by Mertens and colleagues. The agreement was essentially exact for practical purposes, with a coefficient of determination above 0.9999 and a mean absolute percentage error of just 0.51 percent. The worst-case error, arising only when heart rate, resistance, and compliance were simultaneously low, was 3.96 percent, a deviation traced to the limits of the truncated Taylor series at large values of the ratio of diastolic duration to the Windkessel time constant.

The second validation was more demanding, because it pitted the formula against a completely independent model of the circulation. Using a publicly available database of 4,374 simulated adults generated by Charlton and colleagues with a one-dimensional vascular model reproducing age-appropriate cardiovascular distributions from 25 to 75 years, the study compared the new approximation against the clinical surrogate of end-systolic pressure divided by stroke volume, sampled carefully at the end of the small end-systolic flow reversal in the aortic root. The new timing-dependent formula achieved a coefficient of determination of 0.9980 with a mean absolute percentage error of 0.87 percent. Segers’ fixed-coefficient regression, by contrast, yielded 0.9903 with errors up to nearly 15 percent, and the k-equals-zero simplification fell to 0.9610 with maximum errors above 25 percent. The ordering was unambiguous: retaining compliance with a timing-scaled coefficient beats ignoring it outright.

Beyond the curve-fitting, the paper offers a physical intuition for what the coefficient k actually represents. Since Ea approximates end-systolic pressure over stroke volume, and resistance over cycle length approximates mean arterial pressure over stroke volume, the compliance term corresponds to the excess of end-systolic pressure over mean pressure, per unit of stroke volume. That excess depends on two timing-dependent factors. The first is the fraction of the stroke volume still stored in the arterial compartment at the end of systole rather than already run off through the peripheral resistance, which vanishes as diastole shrinks. The second is the fraction of the resulting arterial pressure change that sits above mean arterial pressure, which depends on how the arterial pressure decay is weighted in time. Both factors converge to zero as diastole occupies an ever-smaller slice of the cycle, which is exactly the behavior captured by the squared ratio of diastolic to total cycle duration.

The implications reach beyond theory into the design of empirical studies. Because the ratio of diastolic duration to cycle length varies substantially with heart rate, the apparent relationship between compliance and Ea measured across a population with natural heart-rate variation may not reflect the true contribution of compliance within any single individual. If diastolic fraction happens to covary systematically with compliance across a cohort, the compliance-dependent term could appear nearly constant even though Ea physically depends on compliance in every subject. That mechanism, the paper argues, offers a coherent explanation for the divergent empirical estimates of k that have accumulated since the early 2000s: analyses that reduce Ea to resistance over cycle length and analyses that fit a constant k are simply working at different orders of approximation of the same underlying exponential expression.

The author is careful to delineate the limits of the work. The analysis addresses the interpretation of Windkessel parameters in the systemic circulation only, does not tackle the uncertainty inherent in estimating those parameters from clinical data, excludes the pulmonary circulation, and does not examine how the derived load expressions relate to pressure-flow behavior in living vessels. No new human or animal data were collected, so ethics approval was not required. Even so, the central message is likely to resonate widely among physiologists and clinicians who use Ea to gauge ventricular afterload: the stiffness of the arteries and the rhythm of the heart are not independent contributors to cardiac load but are woven together by the clock of the cardiac cycle, and any formula that ignores that coupling risks misreading how hard the heart truly works.

Subject of Research: The dependence of effective arterial elastance on arterial compliance and cardiac cycle timing in a Windkessel model of the systemic circulation

Article Title: Cardiac timing modulates the contribution of compliance to effective arterial elastance

Article References: Murchie, T. (2026). Cardiac timing modulates the contribution of compliance to effective arterial elastance. Physiological Reports, 14(19), Article e71112. https://doi.org/10.14814/phy2.71112

Image Credits: AI Generated

DOI: 10.14814/phy2.71112

Keywords: effective arterial elastance, arterial compliance, Windkessel model, cardiac timing, diastole, heart rate, ventricular afterload, end-systolic pressure, stroke volume, hemodynamics, cardiovascular physiology, mathematical modeling

Peripheral artery disease affects more than 200 million people worldwide and is driven by the progressive narrowing of arteries outside the heart, most often in the femoropopliteal segment of the leg, where atherosclerosis, thrombosis, and calcification combine to choke off blood supply. In its most severe form, critical limb ischemia, patients suffer rest pain, non-healing wounds, and a high risk of amputation. The standard treatment is endovascular revascularization—typically balloon angioplasty and stenting—but severe calcification stiffens the vessel wall, causing elastic recoil, dissection, and difficulty delivering and expanding devices. Orbital atherectomy was engineered to solve this problem. It uses a diamond-coated crown that orbits eccentrically inside the artery, sanding down calcified plaque while theoretically sparing the vessel from deep injury. The device has been reported to generate microparticles averaging roughly two micrometers in diameter—smaller than red blood cells—suggesting that the debris it produces would be too fine to cause clinically significant blockages downstream.

That assumption has now been directly tested. Researchers at the University of Nebraska Omaha and the University of Nebraska Medical Center obtained ten human femoropopliteal artery segments from tissue donors, all with advanced atherosclerosis and calcification. Nine of the donors were male, with a mean age of 77 years, and the donor cohort reflected the typical risk profile of the disease: all had hypertension, half had diabetes and chronic kidney disease, most had dyslipidemia, and nearly all had smoked. Each artery was mounted in a custom pulsatile flow loop designed to approximate the hemodynamics of the leg artery under resting conditions, complete with a compliance chamber, real-time pressure and flow sensors, and a 100-micrometer filter positioned downstream to capture anything the treatment dislodged.

The experimental protocol mirrored clinical practice. Each vessel underwent baseline imaging and hemodynamic assessment, then treatment with the Diamondback 360 orbital atherectomy system over its dedicated guidewire, with passes at rotational speeds of 60, 90, and 140 thousand revolutions per minute, followed by balloon angioplasty with semi-compliant balloons inflated to nominal pressure. At each stage, micro-computed tomography at voxel resolutions of 50 to 55 micrometers quantified the flow lumen, pressure transducers measured the translesional mean arterial pressure gradient, an ultrasonic flow meter recorded net flow, and the downstream filter was photographed and analyzed with custom image-analysis software to quantify every captured particle.

The headline finding concerns the debris. Orbital atherectomy generated embolic material with a mean captured area of 0.386 square millimeters per particle distribution, and the sizes were alarming: 90 percent of the arteries released fragments of at least 1 millimeter, and 10 percent shed fragments exceeding 5 millimeters—debris capable of obstructing the popliteal or femoral arteries themselves. On average, each specimen released about 87 particles small enough to occlude arterioles, 19 particles in the range of perforator arteries, and roughly 5.5 particles that could block digital arteries, with half to 60 percent of specimens producing emboli in the size range of plantar and tibial vessels. Subsequent balloon angioplasty added smaller debris, averaging 0.143 square millimeters, apparently dislodging plaque that the atherectomy had already loosened. Because embolic protection filters in clinical use may not capture fragments this large, the authors argue the implications for patient safety are considerable.

The study also quantified the benefits that have made the device popular. Flow lumen volume increased significantly and additively across treatment stages, rising by a total of 0.409 milliliters from baseline to after both interventions, with orbital atherectomy contributing 0.180 milliliters and balloon angioplasty adding another 0.229 milliliters. Inner-diameter pulsatility—a measure of how much the lumen itself expands with each heartbeat, and a proxy for luminal compliance—increased from 1.5 percent at baseline to 2.3 percent after the combined treatment, a statistically significant improvement. These results support the core concept behind plaque modification: sanding away calcium does make the channel larger and more distensible, potentially reducing the need for high-pressure ballooning and bailout stenting, a benefit previously reported in trials such as COMPLIANCE 360, which found bailout stenting in just 5.3 percent of atherectomy patients versus 77.8 percent with balloon angioplasty alone.

But the hemodynamic gains were strikingly uneven. The translesional pressure gradient fell by a clinically meaningful margin of more than 10 millimeters of mercury in only 40 percent of the arteries, showed minimal improvement in 50 percent, and actually worsened in 10 percent, in one case because a flow-limiting dissection was created. Net flow improved by at least a quarter in 40 percent of specimens but was unchanged in 30 percent and decreased in the remaining 30 percent, including one artery that lost 41 percent of its flow due to dissection. Dissections were a frequent companion of the treatment, typically occurring at the interface between plaque and vessel wall, and were often exacerbated by the subsequent ballooning. Notably, while the inner lumen became more distensible, the outer diameter pulsatility—measured with both duplex ultrasound and a high-resolution external camera—did not change, suggesting the procedure improves luminal compliance without fundamentally altering the stiffness of the vessel wall itself.

These bench findings dovetail with a growing body of clinical evidence. In the Vascular Study Group of New England registry, orbital atherectomy carried a 4.3 percent embolization rate—77 percent higher than balloon angioplasty and 64 percent higher than stenting—and 68 percent of those embolic events required additional intervention, including open surgery in 11 percent of cases. The LIBERTY 360 registry reported embolization in 7.8 percent of diabetic patients with critical limb ischemia treated with the device, four times the rate seen in non-diabetics. A recent Japanese study of rotational atherectomy with active aspiration found angiographic embolization in more than a third of calcified femoropopliteal procedures and true embolic events in over half. Meanwhile, large analyses of Vascular Quality Initiative and Medicare data have linked atherectomy overall to a 3.7-fold higher risk of major amputation compared with stenting and a 1.5-fold higher risk compared with balloon angioplasty, alongside more major adverse limb events.

The economics add another layer of concern. The Diamondback 360 catheter costs 3,795 dollars in the United States, the average index procedure costs 11,729 dollars, and two-year peripheral artery disease-related costs with atherectomy exceed those of balloon angioplasty or stenting by 6,500 to 8,000 dollars. Medicare outpatient spending on atherectomy ballooned from 86 million dollars in 2011 to 612 million dollars in 2021, a trajectory that has drawn national scrutiny. Against that backdrop, the new study’s authors argue that orbital atherectomy is best reserved for patients with severely calcified lesions in whom plaque modification offers a clear procedural advantage, and should be used cautiously, if at all, in patients at elevated risk of clinically significant distal embolization or when comparable revascularization can be achieved less aggressively. Embolic protection devices, they note, deserve renewed attention given the fragment sizes observed.

The authors are careful to acknowledge the limits of their model. The sample of ten arteries limited statistical power; the specimens were cadaveric and lacked vasoreactivity, healing responses, and thrombosis; the absence of surrounding soft tissue may have altered how the crown interacted with the wall, potentially underestimating debris generation; and the standardized treatment protocol could not capture the operator-dependent variability of real-world practice. Still, the study is the first to systematically combine micro-CT imaging, physiological flow simulation, embolic capture, and pulsatility measurement on the same human arteries across sequential treatment stages, and its central conclusion is difficult to escape: the plaque-modifying benefits of orbital atherectomy are real, but they come bundled with a consistent and substantial shower of embolic debris and vessel wall injury that may explain why the device’s procedural successes have not translated into the superior long-term patency and limb salvage that patients and clinicians hoped for.

Subject of Research: Biomechanical and embolic effects of orbital atherectomy in calcified human femoropopliteal arteries

Article Title: High Embolic Risk with Orbital Atherectomy for Calcified Peripheral Artery Disease

Article References: Gilyazov, R., de Oliveira, B. B., Glushkov, M., Deegan, P., MacTaggart, J., & Kamenskiy, A. (2026). High Embolic Risk with Orbital Atherectomy for Calcified Peripheral Artery Disease. Annals of Biomedical Engineering. https://doi.org/10.1007/s10439-026-04370-9

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04370-9

Keywords: peripheral artery disease, orbital atherectomy, embolization, vascular calcification, femoropopliteal artery, balloon angioplasty, critical limb ischemia, endovascular revascularization, arterial compliance, embolic debris, vessel dissection, biomechanics